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Background:  Increased vascular calcification delineates a higher mortality risk in end stage renal disease subjects. Traditional and nontraditional 
risk factors contribute to vascular calcification among maintenance hemodialysis (MHD) patients. Non-calcium based phosphate binders may have 
a protective role in MHD subjects.
Methods:  We examined 6-year (10/2001-9/2007) survival of 166 MHD patients, aged 53±13 years that underwent Coronary Artery Calcium 
(CAC) scoring. High risk MHD subjects were categorized as scores of CAC 100+. The effect of calcium based phosphate binders (CBPB) alone versus 
sevelamer (a non-calcium based phosphate binder) alone on all-cause mortality was further determined using stepwise Cox regression analysis in 
patients with CAC 100+.
Results:  The Hazard Ratio (HR) of death in MHD subjects with sevelamer decreased from unadjusted model 0.63 [CI 0.26-0.90, p=0.03] to 0.47 
[CI 0.19-0.87, p=0.01] as compared to CBPB when adjusted for demographics, co-morbidity, lipids and other cardiovascular risk, surrogates of bone 
disease, nutritional and inflammatory markers, dialysis dose, and CAC.
Conclusion: Sevelamer demonstrated a protective effect compared to calcium based phosphate binders in the high risk MHD subjects with CAC 
100+ suggesting an anti-atherogenic and anti-inflammatory effect. 
Table 5 HR across CBPB versus sevelamer subjects with CAC 100+ by means of stepwise Cox proportional hazard regression 
analysis models (n=69)
CBPB Sevelamer
Unadjusted* 1 0.63 (0.26-0.90) p=0.03
Case-Mix† 1 0.61 (0.28-0.91) p=0.03
+ Kt/V, albumin, Ca, Phos, CaxP, minerals, iPTH 1 0.59 (0.23-0.90) p=0.03
+LDL, IL-6 1 0.58 (0.21-0.89) p=0.02
+ CAC 1 0.47 (0.19-0.87) p=0.01
95% confidence intervals expressed in parenthesis
*Unadjusted: Sevelamer versus CBPB
†Case-Mix: Sevelamer versus CBPB, age, gender, vintage, diabetes mellitus, hypertension, statin therapy, smoking, family 
history of premature CVD, Ethnicity (Hispanic vs. other), Race (Black vs. other), BMI
BMI = body mass index; Ca = calcium; CAC = log coronary artery calcium; CaxP = calcium-phosphorus product; CBPB = 
calcium based phosphate binder; CVD = cardiovascular disease; HR = Hazard Ratio; IL-6 = interleukin 6; iPTH = intact 
parathyroid hormone; LDL = low dense lipoprotein; Phos = phosphorus
